Sildenafil is a candidate drug for Alzheimer’s disease: Real-world patient and RNA-sequencing data observations in patient-induced pluripotent stem cells-derived neurons
Yi‐Chen Li(Harbin Medical University), Feixiong Cheng(Cleveland Clinic Lerner College of Medicine), Andrew A. Pieper(Cornell University), Chien‐Wei Chiang(The Ohio State University), Dhruv Gohel(Maharaja Sayajirao University of Baroda), Pengyue Zhang(Indiana University Health), Jeffrey L. Cummings(University of California, Los Angeles)
Cited by 0
Related Papers
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
|Nature Genetics|2011|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k
Positron Emission Tomography in Evaluation of Dementia
|JAMA|2001|952
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818